Phase II study of ibrutinib plus venetoclax combination therapy in subjects with chronic lymphocytic or small cell lymphocytic leukemia for whom they received no treatment
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PHARMACYCLI CS LLC
- Phase: II
- Execution start: 07/04/2017
- End of execution: 30/04/2021
- PI: MANUEL JURADO CHACON